Evicenter
P&T meetings

Ulixacaltamide

Essential tremor

Regulatory submission
NDA submitted by February 2026
Launch
Not announced
Last updated
78 sources

Product information and disease descriptionProduct descriptionProduct information

Product comparison

2 evidence topics · 6 sources

Head-to-head comparisons with established essential tremor therapies

No evidence found.

Placebo-controlled study of NBI-827104

“NBI-827104 did not meet the primary or secondary efficacy endpoints.” (opens the source at this quote in a new tab)

Adverse events in the SAGE-324 KINETIC trial

“somnolence, dizziness, fatigue, and balance disorder.” (opens the source at this quote in a new tab)